Show simple item record

dc.contributor.authorGrimnes, Gro
dc.contributor.authorBhoelan, Soerajja
dc.contributor.authorHindberg, Kristian
dc.contributor.authorDavids, Mark
dc.contributor.authorNieuwdorp, Max
dc.contributor.authorMollnes, Tom E.
dc.contributor.authorMichelsen, Annika Elisabet
dc.contributor.authorUeland, Thor
dc.contributor.authorBrækkan, Sigrid K.
dc.contributor.authorHansen, John-Bjarne
dc.contributor.authorTichelaar, Ynse Ieuwe Gerardus Vladimir
dc.date.accessioned2022-02-16T10:12:19Z
dc.date.available2022-02-16T10:12:19Z
dc.date.issued2021-08-24
dc.description.abstractRationale - Inflammation is present in several conditions associated with risk of venous thromboembolism. The gut microbiome might be a source of systemic inflammation and activation of coagulation, by translocation of lipopolysaccharides from gram-negative bacteria to the systemic circulation.<p> <p>Objective - To investigate whether a vancomycin-induced shift of the gut microbiome in a gram-negative direction influences systemic inflammation and plasma factor (F) VIII procoagulant activity (FVIII:C).<p> <p>Methods and Results - We performed a randomized controlled trial including 43 healthy volunteers aged 19 to 37 years. Twenty-one were randomized to 7 days of oral vancomycin intake and 22 served as controls. Feces and blood were sampled at baseline, the day after the end of intervention, and 3 weeks after intervention. Gut microbiome composition was assessed by amplicon sequencing. FVIII:C was measured using an activated partial thromboplastin time-based assay, cytokines were measured using multiplex technology, complement activation was measured using the enzyme-linked immunosorbent assay, and high-sensitivity C-reactive protein (CRP) was measured by an immunoturbidimetric assay. Vancomycin intake reduced gut microbiome diversity and increased the abundance of gram-negative bacteria. Change in FVIII:C in the intervention group was +4 IU/dL versus −6 IU/dL (p = 0.01) in the control group. A similar change was observed for log-transformed CRP (+0.21 mg/dL vs. −0.25 mg/dL, p = 0.04). The cytokines and complement activation markers remained similar in the two groups.<p> <p>Conclusion - The found slight increases in FVIII:C and CRP levels might support the hypothesis that a vancomycin-induced gram-negative shift in the gut microbiome could induce increased systemic inflammation and thereby a procoagulant state.en_US
dc.identifier.citationGrimnes, Bhoelan S, Hindberg, Davids, Nieuwdorp, Mollnes, Michelsen, Ueland, Brækkan, Hansen, Tichelaar YIGV. Impact of a Vancomycin-Induced Shift of the Gut Microbiome in a Gram-Negative Direction on Plasma Factor VIII:C Levels: Results from a Randomized Controlled Trial. Thrombosis and Haemostasis. 2021;0:1-12en_US
dc.identifier.cristinIDFRIDAID 1933068
dc.identifier.doi10.1055/s-0041-1733906
dc.identifier.issn0340-6245
dc.identifier.urihttps://hdl.handle.net/10037/24066
dc.language.isoengen_US
dc.publisherThieme Gruppeen_US
dc.relation.journalThrombosis and Haemostasis
dc.rights.accessRightsopenAccessen_US
dc.rights.holder© 2021. Thieme. All rights reserved.en_US
dc.titleImpact of a Vancomycin-Induced Shift of the Gut Microbiome in a Gram-Negative Direction on Plasma Factor VIII:C Levels: Results from a Randomized Controlled Trialen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record